Each sustained-release tablet contains Natural Micronized Progesterone SR 200 mg or Natural Micronized Progesterone SR 300 mg.

Fulgest SR Tablets contain Natural Micronized Progesterone in a sustained-release formulation designed to provide prolonged progesterone availability with once-daily dosing. It helps restore progesterone deficiency, regulate the menstrual cycle, support normal endometrial maturation, prevent endometrial hyperplasia during estrogen therapy, and provide luteal phase support in women undergoing assisted reproductive techniques. The sustained-release formulation ensures consistent hormone levels and improved patient convenience.

Fulgest SR Tablets are indicated for the treatment of secondary amenorrhea, functional uterine bleeding due to hormonal imbalance, progesterone deficiency, and luteal phase support in women participating in fertilization programmes. They are also indicated for the prevention of endometrial hyperplasia in postmenopausal women receiving estrogen replacement therapy.

Natural Micronized Progesterone is a naturally occurring steroid hormone that acts on the endometrium by converting it from the proliferative phase to the secretory phase, thereby preparing the uterus for implantation and maintenance of pregnancy. It counteracts the proliferative effects of estrogen on the endometrium, helps regulate the menstrual cycle, supports reproductive function, and reduces the risk of endometrial hyperplasia in women receiving estrogen therapy.

Prevention of Endometrial Hyperplasia: 200 mg orally once daily at bedtime for 12 consecutive days during each 28-day cycle in postmenopausal women receiving daily conjugated estrogen therapy. Treatment of Secondary Amenorrhea: 400 mg orally once daily at bedtime for 10 days, or as directed by the physician.

Fulgest SR Tablets are contraindicated in patients with known hypersensitivity to Progesterone or any component of the formulation. They should not be used in patients with undiagnosed abnormal genital bleeding, known, suspected, or previous breast cancer, or other conditions where progesterone therapy is contraindicated.